Everest (EG) Q2 2026 Earnings Call Transcript

Everest Group reported Q2 2026 net operating income of $585m and after-tax net operating EPS of $14.85, with annualized after-tax ROE of 14.9% and book value per share up 12% YoY (to ~$408, excluding unrealized gains). Core underwriting delivered $317m of underwriting income on a 90.0% combined ratio (cat losses contributing 2.7 pts), while property catastrophe renewal pricing declined 10% vs the broader market’s 15%–20%. Capital returns accelerated: the company repurchased $395m of shares (1.2m shares at ~$342) plus dividends for an 81% payout ratio, and it has deployed ~$1.5b in buybacks since Jan. 2025, reducing shares by >10%. Management also increased reserves (notably +$55m for the Baltimore Bridge matter; North America casualty strengthening just under $200m), but maintained confidence in profitability and expects consistent near-term loss ratio ranges as it reports more granular “core business” results.

Analysis

Near term, the stock should trade on whether investors view the reserve action as proactive or as a first admission that casualty long-tail is still deteriorating. I think the market is underestimating the signaling value of taking pain now, because it reduces the probability of a larger third-quarter reset; the real catalyst is the upcoming loss-triangle disclosure and annual reserve study, which will separate one-off prudence from a persistent loss-trend problem.

The bigger second-order winner is the capital base, not the top line: higher buybacks, a running runoff of legacy capital, and the sidecar structure all shift Everest toward a more fee-like, less balance-sheet-intensive earnings mix. That supports multiple expansion if reserve visibility improves, but it also means competitors still chasing casualty or cat volume — especially carriers with weaker reserve discipline — may be forced into a worse tradeoff between growth and underwriting quality over the next 6-12 months.

Contrarian view: consensus is likely too focused on the lower premium base and the reserve charge, missing that the company is intentionally shrinking bad business while recycling capital into repurchases at an attractive valuation. The falsifier is simple: if the Q3 reserve study adds another meaningful casualty step-up, or if buybacks fall below the implied floor, the thesis shifts from compounding to damage control.

Time horizon matters: the next few days are about headline volatility; the next 1-3 months are about reserve confirmation; the next 6-18 months are about whether the cleaner reporting and capital return machine can drive a higher ROE multiple.

Key Decisions for Investors

• Buy EG on post-earnings weakness and hold 6-18 months; the setup is best if the market overreacts to reserve noise before the Q3 triangle release. Risk/reward improves if the stock de-risks while buybacks stay above a $300M quarterly floor.
• Pair trade: long EG / short RNR for the next 1-3 months to express the view that Everest is managing casualty/cat exposure more proactively while preserving capital return. Falsifier: a major cat event or a sharp re-hardening in reinsurance pricing.
• Trim or avoid adding if EG rallies 10%+ before the third-quarter reserve study and loss triangles; the next disclosure is a real event risk that can compress the multiple if casualty development worsens.
• Watchlist alert: if buybacks continue above $350M per quarter and reserve additions do not recur in Q3, add to EG on any sector-wide selloff; if casualty reserves reaccelerate, cut the position immediately.